Condition
Influenza Vaccine Allergy
Total Trials
3
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 4 (1)
Trial Status
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06446232RecruitingPrimary
Influenza Vaccine Effectiveness in Among Young Children in Taiwan
NCT03654937Phase 4Completed
Immune Response and Risk of Side Effects After Influenza Vaccination in Athletes
NCT01310374CompletedPrimary
Immune Response Study of Influenza Vaccine
Showing all 3 trials